We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EU’s IMI Pursues New Drug Development Tools, More Exclusivity
EU’s IMI Pursues New Drug Development Tools, More Exclusivity
A European public-private partnership is launching a new $4.5 billion decade-long effort to improve the success rate of clinical trials on certain drugs by 30 percent and boost exclusivity to make manufacturing treatments more enticing.